Loading clinical trials...
Loading clinical trials...
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Conditions
Interventions
NOV-205
Locations
6
United States
Borland-Grooover Clinic
Jacksonville, Florida, United States
Venture Research Institute, LLC
Miami, Florida, United States
Orlando Immunology Center
Orlando, Florida, United States
MetroWest Medical Center
Framingham, Massachusetts, United States
UMASS Memorial Medical Center
Worcester, Massachusetts, United States
Cumberland Research Associates, LLC
Fayetteville, North Carolina, United States
Start Date
March 1, 2010
Primary Completion Date
December 1, 2010
Completion Date
December 1, 2010
Last Updated
July 25, 2022
NCT06953479
NCT04162938
NCT03135886
NCT05968573
NCT01644903
NCT05368974
Lead Sponsor
Cellectar Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions